RIG-I Monoclonal Antibody (Clone 1E3)

Retinoic acid-inducible gene I (RIG-I), also known as DDX58, is a cytosolic DExD/H-box RNA helicase and an immune sensing receptor encoded by DDX58 in humans.¹ It is composed of a C-terminal repressor domain, a central RNA helicase domain, and two N-terminal caspase recruitment domains (CARDs).^1,2 Following recognition of viral dsRNA by the C-terminal and helicase domains, the helicase domain induces an ATP-dependent conformational change, allowing for interaction of the CARD domains with mitochondrial antiviral-signaling protein (MAVS) and induction of a type I interferon (IFN) response.^1,2,3 RIG-I levels are elevated in the epidermis of patients with psoriasis.² DDX58 expression is decreased in tumor tissues from patients with hepatocellular carcinoma (HCC) compared to nontumor hepatic tissue, and low DDX58 expression is associated with poor disease prognosis.⁴ Cayman’s RIG-I Monoclonal Antibody (Clone 1E3) can be used for Western blot, ELISA, and immunohistochemistry applications. The antibody recognizes RIG-I at 106.6 kDa from human and mouse samples.

WARNING This product is not for human or veterinary use.

1. Hartmann, G. Nucleic acid immunity. Advances in Immunology 133, 121-169 (2017).

2. Matsumiya, T., and Stafforini, D.M. Function and regulation of retinoic acid-inducible gene-I. Crit. Rev. Immunol. 30(6), 489-513 (2010).

3. Takeuchi, O., and Akira, S. Innate immunity to virus infection. Immunol. Rev. 277(1), 75-86 (2009).

4. Hou, J., Zhou, Y., Zheng, Y., et al. Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell. 25(1), 49-63 (2014).